Simplify and standardise clinical trial outcome measures, including steroid-sparing as an outcome. Develop data sharing approaches related to biomarkers, clinical data and lab samples. Propel quality of life-driven studies (eg, fatigue). Increase participant representativeness in clinical trials (e.g., minority, paediatric and cutaneous lupus erythematosus).
| Define the lupus spectrum. Perform longitudinal studies of prognostic and diagnostic biomarkers. Drive clinical and lab-based measures for individualised treatments. Identify and support development of treatment adherence strategies that work for lupus and communicate them to patients and providers.
| Build the case for World Health Organisation (WHO) prioritisation of lupus. Develop standardised and specialised, expert-driven care pathways. Drive telehealth advances and reimbursement, and build on current infrastructures. Explore broader partnering. Leverage social media. Develop evidence base for interventions, including standardised endpoints/outcomes. Provide payor education and establish alignment.
|